Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.37 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5378919 | 0.98 | LMNA (0.45) | LMNACYP2C19RECQLCNR1CNR2 | |
| SCHEMBL5375422 | 0.98 | LMNA (0.45) | LMNACYP2C19RECQLCNR1CNR2 | |
| SCHEMBL8761552 | 0.79 | SLC6A3 (0.44) | LMNACYP3A4 | |
| SCHEMBL6856654 | 0.79 | CYP3A4 (0.39) | LMNACYP2C19RECQLKMT2AHPGD | |
| SCHEMBL5861434 | 0.79 | KMT2A (0.40) | KMT2AEPHX2HPGDRAB9AMEN1 | |
| SCHEMBL6856652 | 0.77 | SMN1; SMN2 (0.41) | LMNACYP2C19RECQLKMT2AHPGD | |
| SCHEMBL6856741 | 0.77 | SMN1; SMN2 (0.41) | LMNACYP2C19RECQLKMT2AHPGD | |
| SCHEMBL10301488 | 0.76 | ALDH1A1 (0.52) | LMNACYP2C19CNR1CNR2KMT2A | |
| SCHEMBL3308217 | 0.76 | CYP2C19 (0.69) | LMNACYP2C19 | |
| SCHEMBL6195187 | 0.76 | ATM (0.39) | RECQLCNR2KMT2AEPHX2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7309702-B2 | 4-(3-Phenyl-3-carbocycloylpropyl)-1-phenyl- or pyridylpiperazine derivatives: 1-(2-methoxyphenyl)-4-[3-(benzoyl)-3-(phenyl)propyl]piperazine oxalate; serotonin receptor antagonists; Alzheimer's disease | AVERA PHARMACEUTICALS, INC. (US) | 2007-12-18 | — | — | US | disclosed |
| US-7001908-B2 | Arylpiperazines having activity at the serotonin 1A receptor | AVERA PHARMACEUTICALS, INC. (US) | 2006-02-21 | — | — | US | disclosed |
| US-20060009464-A1 | Arylpiperazines having activity at the serotonin 1A receptor | ELI LILLY AND COMPANY | 2006-01-12 | — | — | US | disclosed |
| US-20050282817-A1 | 4-(3-Phenyl-3-carbocycloylpropyl)-1-phenyl- or pyridylpiperazine derivatives: 1-(2-methoxyphenyl)-4-[3-(benzoyl)-3-(phenyl)propyl]piperazine oxalate; serotonin receptor antagonists; obesity | NOKIA CORPORATION (FI) | 2005-12-22 | — | — | US | disclosed |
| US-6946579-B2 | Arylpiperazines having activity at the serotonin 1A receptor | ELI LILLY AND COMPANY (US) | 2005-09-20 | — | — | US | disclosed |
| EP-0924205-B1 | Arylpiperazines having activity at the serotonin 1a receptor | LILLY CO ELI (US) | 2005-05-25 | — | — | EP | disclosed |
| EP-1514559-A1 | Arylpiperazines having activity at the serotonin 1a receptor | Eli Lilly and Company (US) | 2005-03-16 | — | — | EP | disclosed |
| US-20040049083-A1 | 3-carbocycle carbonyl-3-phenylpropionaldehyde intermediates and preparation by alkylating a carbocycle benzyl ketone with an allyl halide and oxidizing the product | ELI LILLY AND COMPANY | 2004-03-11 | — | — | US | disclosed |
| US-20040044009-A1 | Drug abuse; cental nervous system disorders; cognition activators | ELI LILLY AND COMPANY | 2004-03-04 | — | — | US | disclosed |
| US-6660859-B2 | Arylpiperzine derivatives are useful for treatment of anxiety, depression, hypertension, cognitive disorders, sexual dysfunction, brain trauma, memory loss, eating disorders, obesity, substance abuse, and obsessive-compulsive diseases | ELI LILLY AND COMPANY | 2003-12-09 | — | — | US | disclosed |
| US-6645967-B2 | Administering to a patient a serotonin reuptake inhibitor in combination with an effective amount of arylpiperazines having activity at the serotonin 1A receptor | ELI LILLY AND COMPANY | 2003-11-11 | — | — | US | disclosed |
| US-20030027831-A1 | Arylpiperzine derivatives are useful for treatment of anxiety, depression, hypertension, cognitive disorders, sexual dysfunction, brain trauma, memory loss, eating disorders, obesity, substance abuse, and obsessive-compulsive diseases | XU YAO-CHANG (US) | 2003-02-06 | — | — | US | disclosed |
| US-6514976-B2 | For therapy of symptoms caused by withdrawal or partial withdrawal from the use of tobacco or of nicotine; for therapy of anxiety | ELI LILLY AND COMPANY | 2003-02-04 | — | — | US | disclosed |
| US-20030008879-A1 | For therapy of symptoms caused by withdrawal or partial withdrawal from the use of tobacco or of nicotine; for therapy of anxiety | KOHLMAN DANIEL TIMOTHY (US) | 2003-01-09 | — | — | US | disclosed |
| US-20020169170-A1 | Administering to a patient a serotonin reuptake inhibitor in combination with an effective amount of arylpiperazines having activity at the serotonin 1A receptor | GODFREY ALEXANDER GLENN (US) | 2002-11-14 | — | — | US | disclosed |
| US-6358958-B2 | MONO OR BICYCLIC ARYL OR HETERARYL SUBSTITUTED PIPERIZIN DERIVATIVES USEFUL FOR TREATING ANXIETY, DEPRESSION, HYPERTENSION, COGNITIVE DISORDER, PSYCHOSIS, SLEEP DISORDER, BRAIN TRAUMA, MEMORY LOSS, DRUG ABUSE, MIGRAINE AND OBESITY | ELI LILLY AND COMPANY | 2002-03-19 | — | — | US | disclosed |
| US-20010003749-A1 | Mono or bicyclic aryl or heteraryl substituted piperizin derivatives useful for treating anxiety, depression, hypertension, cognitive disorder, psychosis, sleep disorder, brain trauma, memory loss, drug abuse, migraine and obesity | GODFREY ALEXANDER GLENN (US) | 2001-06-14 | — | — | US | disclosed |
| US-6239135-B1 | ALLEVIATING THE SYMPTOMS OF NICOTINE AND TOBACCO WITHDRAWAL. | ELI LILLY AND COMPANY | 2001-05-29 | — | — | US | disclosed |
| WO-1999031077-A1 | ARYLPIPERAZINES HAVING ACTIVITY AT THE SEROTONIN 1A RECEPTOR | ELI LILLY AND COMPANY (US) | 1999-06-24 | — | — | WO | disclosed |
| EP-0924205-A1 | Arylpiperazines having activity at the serotonin 1a receptor | ELI LILLY AND COMPANY (US) | 1999-06-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030027831-A1 | Arylpiperzine derivatives are useful for treatment of anxiety, depression, hypertension, cognitive disorders, sexual dysfunction, brain trauma, memory loss, eating disorders, obesity, substance abuse, and obsessive-compulsive diseases | HTR2C, HTR3C, HCRTR1 | LMNA 2749/4885CYP2C19 410/4885RECQL 3294/4885 |
| US-20060009464-A1 | Arylpiperazines having activity at the serotonin 1A receptor | HTR1A, HTR2A, HTR3A | LMNA 4610/4885CYP2C19 588/4885RECQL 4366/4885 |
| US-20040049083-A1 | 3-carbocycle carbonyl-3-phenylpropionaldehyde intermediates and preparation by alkylating a carbocycle benzyl ketone with an allyl halide and oxidizing the product | HTR3C, HTR3A, HTR2C | LMNA 3630/4885CYP2C19 274/4885RECQL 4818/4885 |
| US-20010003749-A1 | Mono or bicyclic aryl or heteraryl substituted piperizin derivatives useful for treating anxiety, depression, hypertension, cognitive disorder, psychosis, sleep disorder, brain trauma, memory loss, drug abuse, migraine and obesity | HTR1A, HTR2C, HTR3B | LMNA 1376/4885CYP2C19 293/4885RECQL 3066/4885 |
| US-20020169170-A1 | Administering to a patient a serotonin reuptake inhibitor in combination with an effective amount of arylpiperazines having activity at the serotonin 1A receptor | HTR3C, TPH1, HTR6 | LMNA 2780/4885CYP2C19 421/4885RECQL 2848/4885 |
| US-20030008879-A1 | For therapy of symptoms caused by withdrawal or partial withdrawal from the use of tobacco or of nicotine; for therapy of anxiety | HTR1A, HTR1B, HTR3A | LMNA 4036/4885CYP2C19 755/4885RECQL 4118/4885 |
| US-20040044009-A1 | Drug abuse; cental nervous system disorders; cognition activators | HTR6, HTR1A, CNR1 | LMNA 4647/4885CYP2C19 1032/4885RECQL 4617/4885 |
| US-20050282817-A1 | 4-(3-Phenyl-3-carbocycloylpropyl)-1-phenyl- or pyridylpiperazine derivatives: 1-(2-methoxyphenyl)-4-[3-(benzoyl)-3-(phenyl)propyl]piperazine oxalate; serotonin receptor antagonists; obesity | HTR3A, HTR3C, HTR1A | LMNA 4315/4885CYP2C19 348/4885RECQL 4596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.